Read more

December 18, 2024
2 min watch
Save

VIDEO: Updates in CAR T-cell therapy from ASH 2024

SAN DIEGO — Paolo Caimi, MD, spoke with Healio about research updates on chimeric antigen receptor T-cell therapy presented at ASH Annual Meeting and Exposition.

Caimi, a physician and clinical investigator at Cleveland Clinic, discussed updates presented on the use of rapcabtagene autoleucel (YTB323, Novartis) in patients with relapsed/refractory diffuse large B-cell lymphoma.

He also discussed interim results from a phase 2 trial on the use of tandem non-cryopreserved CAR T-cell therapy in patients with relapsed or refractory DLBCL.

Caimi noted that the agent had “comparable activity” compared with other CAR T-cell therapies and has a good safety profile.

“It will be interesting to see whether these products delivered fresh have more activity or [if] they’re more well tolerated in terms of toxicity,” he added.

References:

  • Riedell PA, et al. Abstract 67. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
  • Shah NN, et al. Abstract 68. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.